Cramer Rosenthal Mcglynn LLC Grows Holdings in Natus Medical Inc (NASDAQ:BABY)

Share on StockTwits

Cramer Rosenthal Mcglynn LLC increased its position in Natus Medical Inc (NASDAQ:BABY) by 19.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,534,996 shares of the medical equipment provider’s stock after acquiring an additional 246,269 shares during the quarter. Cramer Rosenthal Mcglynn LLC owned about 4.51% of Natus Medical worth $39,434,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Comerica Bank increased its holdings in Natus Medical by 1.2% in the 1st quarter. Comerica Bank now owns 33,383 shares of the medical equipment provider’s stock worth $856,000 after acquiring an additional 384 shares in the last quarter. Piedmont Investment Advisors Inc. increased its holdings in Natus Medical by 4.8% in the 1st quarter. Piedmont Investment Advisors Inc. now owns 8,406 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 387 shares in the last quarter. Royce & Associates LP increased its holdings in Natus Medical by 55.4% in the 1st quarter. Royce & Associates LP now owns 1,100 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 392 shares in the last quarter. Bridge City Capital LLC increased its holdings in Natus Medical by 0.5% in the 2nd quarter. Bridge City Capital LLC now owns 85,910 shares of the medical equipment provider’s stock worth $2,207,000 after acquiring an additional 423 shares in the last quarter. Finally, Arizona State Retirement System increased its holdings in Natus Medical by 1.2% in the 2nd quarter. Arizona State Retirement System now owns 52,751 shares of the medical equipment provider’s stock worth $1,355,000 after acquiring an additional 645 shares in the last quarter. 91.56% of the stock is owned by institutional investors.

BABY stock remained flat at $$31.92 during midday trading on Friday. The company’s stock had a trading volume of 289,334 shares, compared to its average volume of 165,325. Natus Medical Inc has a 1-year low of $23.53 and a 1-year high of $37.90. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.70 and a quick ratio of 1.18. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of 22.48 and a beta of 0.57. The business has a 50 day moving average price of $29.31 and a 200 day moving average price of $26.74.

Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Thursday, July 25th. The medical equipment provider reported $0.34 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.30 by $0.04. Natus Medical had a positive return on equity of 10.79% and a negative net margin of 7.38%. The business had revenue of $125.50 million during the quarter, compared to the consensus estimate of $122.85 million. During the same period in the prior year, the company posted $0.35 EPS. The firm’s revenue for the quarter was down 4.0% compared to the same quarter last year. On average, analysts expect that Natus Medical Inc will post 1.27 EPS for the current year.

Several research firms recently issued reports on BABY. BidaskClub raised shares of Natus Medical from a “strong sell” rating to a “sell” rating in a report on Tuesday, July 23rd. Zacks Investment Research upgraded Natus Medical from a “strong sell” rating to a “hold” rating in a research note on Wednesday, June 26th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $36.00.

In other news, VP Austin Francis Noll III sold 20,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $31.14, for a total transaction of $622,800.00. Following the completion of the transaction, the vice president now directly owns 105,193 shares in the company, valued at approximately $3,275,710.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ken Ludlum sold 12,632 shares of the stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $31.94, for a total value of $403,466.08. Following the transaction, the director now owns 39,406 shares of the company’s stock, valued at $1,258,627.64. The disclosure for this sale can be found here. 1.65% of the stock is currently owned by corporate insiders.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Featured Article: Stocks Increasing Dividends

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc (NASDAQ:BABY).

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Rockhopper Exploration  Earns Buy Rating from Peel Hunt
Rockhopper Exploration Earns Buy Rating from Peel Hunt
SDX Energy  Stock Rating Reaffirmed by Peel Hunt
SDX Energy Stock Rating Reaffirmed by Peel Hunt
Liberum Capital Reiterates Buy Rating for Science in Sport
Liberum Capital Reiterates Buy Rating for Science in Sport
Salt Lake Potash  Stock Rating Reaffirmed by Shore Capital
Salt Lake Potash Stock Rating Reaffirmed by Shore Capital
FinnCap Reiterates “Corporate” Rating for Zambeef Products
FinnCap Reiterates “Corporate” Rating for Zambeef Products
Weir Group  Rating Lowered to Neutral at JPMorgan Chase & Co.
Weir Group Rating Lowered to Neutral at JPMorgan Chase & Co.


© 2006-2019 Ticker Report